Preview

Российский журнал гастроэнтерологии, гепатологии, колопроктологии

Расширенный поиск

Запор функционального происхождения

https://doi.org/10.22416/1382-4376-2017-27-5-105-112

Полный текст:

Об авторах

Ю. О. Шульпекова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова»
Россия


А. А. Курбатова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова»
Россия


А. В. Седова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова»
Россия


Список литературы

1. Шептулин А.А., Визе-Хрипунова М.А. Римские кри- терии синдрома раздраженного кишечника IV пере- смотра: есть ли принципиальные изменения? Рос журн гастроэнтерол гепатол колопроктол 2016;26(5):99-103.

2. Drossman D.A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016 Feb 19; pii: S0016-5085(16)00223-7.

3. Simren M., Palsson O.S., Whitehead W.E. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep 2017; 19(4): 15.

4. Barbara G., Feinle-Bisset C., Ghoshal U.C. et al. The intestinal microenvironment and functional gastrointesti- nal disorders. Gastroenterology 2016;150:1305-18.e8.

5. Fang X., Francisconi C.F., Fukudo S., Gerson M.J., Kang J.Y., Schmulson Wasserman M.J., Sperber A.D. Multicultural Aspects in Functional Gastrointestinal Disorders (FGIDs). Gastroenterology 2016 Feb 15. pii: S0016-5085(16)00179-7.

6. Lee H.J., Choi J.K., Ryu H.S., Choi C.H., Kang E.H., Park K.S., Min Y.W., Hong K.S. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. J Neuro- gastroenterol Motil 2017 Jan 30;23(1):9-19.

7. Schmulson Wasserman M.J., Drossman D.A. What Is New in Rome IV. J Neurogastroenterol Motil 2017 Apr; 23(2): 151-63.

8. Anbardan S.J., Daryani N.E., Fereshtehnejad S.M., Taba Taba Vakili S., Keramati M.R., Ajdarkosh H. Gender Role in Irritable Bowel Syndrome: A Comparison of Irritable Bowel Syndrome Module (ROME III) Between Male and Female Patients. J Neurogastroenterol Motil 2012 Jan;18(1):70-7.

9. Shahid S., Ramzan Z., Maurer A.H., Parkman H.P., Fisher R.S. Chronic idiopathic constipation: more than a simple colonic transit disorder. J Clin Gastroenterol 2012 Feb;46(2):150-4.

10. Ribas Y., Saldaña E., Martí-Ragué J., Clavé P. Prevalence and pathophysiology of functional constipa- tion among women in Catalonia, Spain. Dis Colon Rectum 2011 Dec;54(12):1560-9.

11. Saito Y.A. The role of genetics in IBS. Gastroenterol Clin N Am 2011 Mar;40(1):45-67.

12. Deiteren, A., Camilleri M., Burton D., McKinzie S., Rao A., Zinsmeister A.R. Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome. Dig Dis Sci 2010;55:384-91.

13. Di Stefano M., Miceli E., Missanelli A., Mazzocchi S., Corazza G.R. Meal induced rectosigmoid tone modifica- tion: a low caloric meal accurately separates functional and organic gastrointestinal disease patients. Gut 2006 Oct;55(10):1409-14.

14. El-Salhy M., Seim I., Chopin L., Gundersen D., Hatlebakk J.G., Hausken T. Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 2012 Jun 1;4:2783-800.

15. Abrahamsson H., Ostlund-Lindqvist A.M., Nilsson R., Simrén M., Gillberg P.G. Altered bile acid metabo- lism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol 2008;43(12):1483-8.

16. Triantafyllou K., Chang C., Pimentel M. Methanogens, methane and gastrointestinal motility. J Neurogastroenterol Motil 2014 Jan; 20(1):31-40.

17. Agrawal A., Whorwell P., Houghton L. Is abdominal distension related to delayed small and large transit transit in patients with constipation predominant irritable bowel syndrome.Gastroenterology 2006; 130(Suppl 2):632.

18. DeLegge M. (ed.). Nutrition and Gastrointestinal Disease. © Humana Press Inc.; 2008. 338 p.

19. Buchman A.L. Nutritional Care of the Patient with Gastrointestinal Disease. CRC Press; 2015. 441 p.

20. Tuck C.J., Muir J.G., Barrett J.S., Gibson P.R. Fermentable oligosaccharides, disaccharides, monosaccha- rides and polyols: Role in irritable bowel syndrome. Exp Rev Gastroenterol Hepatol 2014;15:1-16.

21. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., Белоусова Е.А., Васильев С.В., Головенко О.В., Национальная школа гастроэнтерологов, гепатологов www.gastro-j.ru National college of gastroenterologists, hepatologists Хубезов Д.А., Чашкова Е.Ю., Чибисов Г.И., Шептулин А.А., Шифрин О.С., Яновой В.В. Клинические рекоменда- ции Российской гастроэнтерологической ассоциации, Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишеч- ника. Рос журн гастроэнтерол гепатол колопроктол 2014; 24(2):92-101

22. Синдром раздраженного кишечника: Глобальная пер- спектива. Практические рекомендации Всемирной гастроэнтерологической организации. Интернет-сайт http://www.worldgastroenterology.org - 1 июля 2017 г.

23. Whorwell P.J. Do Probiotics Improve Symptoms in Patients with Irritable Bowel Syndrome? Ther Adv Gastroenterol 2009 Jul; 2(Suppl 4):37-44.

24. Ford A.C., Quigley E.M., Lacy B.E. et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547-61.

25. Aragon G., Graham D.B., Borum M., Doman D.B. Probiotic Therapy for Irritable Bowel Syndrome. Gastroenterol Hepatol (N.Y.) 2010 Jan; 6(1):39-44.

26. Carabotti M., Scirocco A., Maselli M.A., Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015 Apr-Jun; 28(2):203-9.

27. O’Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O’Sullivan G.C., Kiely B., Collins J.K., Shanahan F., Quigley E.M. Lactobacillus and bifidobacterium in irritable bowel syndrome: symp- tom responses and relationship to cytokine profiles. Gastroenterology 2005 Mar; 128(3):541-51.

28. Marteau P., Cuillerier E., Meance S., Gerhardt M.F., Myara A., Bouvier M., Bouley C., Tondu F., Bommelaer G., Grimaud J.C. Bifidobacterium animalis strain DN-173010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002 Mar; 16(3):587-93.

29. Agrawal A., Houghton L.A., Morris J., Reilly B., Guyonnet D., Goupil Feuillerat N., Schlumberger A., Jakob S., Whorwell P.J. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009 Jan; 29(1):104-14.

30. Yang Y.X., He M., Hu G., Wei J., Pages P., Yang X.H., Bourdu-Naturel S. Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol 2008; 14(40):6237-43.

31. Mouret M., Mercier C.H. et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicen- tre, randomized, doubleblind, controlled trial. Aliment Pharmacol Ther 2007; 26:475-86.

32. Marteau P., Guyonnet D., Lafaye de Micheaux P., Gelu S. A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms. Neurogastroenterol Motil 2013 Apr;25(4):331-e252.

33. Guyonnet D., Woodcock A., Stefani B., Trevisan C., Hall C. Fermented milk containing Bifidobacterium lactis DN-173010 improved self-reported digestive com- fort amongst a general population of adults. A random- ized, open-label, controlled, pilot study. J Dig Dis 2009 Feb;10(1):61-70.

34. Krammer H.J., von Seggern H., Schaumburg J., Neumer F. Effect of Lactobacillus casei Shirota on colonic transit time in patients with chronic constipation. Сoloproctology 2011;33:109-13.

35. Mazlyn M.M., Nagarajah L.H., Fatimah A., Norimah A.K., Goh K.L. Effects of a probiotic fermented milk on functional constipation: a randomized, double- blind, placebo-controlled study. J Gastroenterol Hepatol 2013 Jul; 28(7):1141-7.

36. Waller P.A., Gopal P.K., Leyer G.J., Ouwehand A.C., Reifer C., Stewart M.E., Miller L.E. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol 2011 Sep; 46(9):1057-64.

37. Ivashkin V., Drapkina O., Poluektova Ye., Kuchumova S., Sheptulin A., Shifrin O. The effect of a multi-strain probiotic on the symptoms and small intestinal bacterial overgrowth in constipation-predominant irritable bowel syndrome: a randomised, simple-blind, placebo- controlled trail. Am J Clin Med Res 2014; 3(2):18-23.

38. Eales J., Gibson P., Whorwell P., Kellow J., Yellowlees А., Perry R.H.J., Edwards M., King S., Wood H., Glanville J. Systematic review and meta-anal- ysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastroin- testinal discomfort in the general adult population. Ther Adv Gastroenterol 2017 Jan; 10(1): 74-88.

39. Riezzo G., Orlando A., D’Attoma B., Guerra V., Valerio F., Lavermicocca P., De Candia S., Russo F. Randomised clinical trial: efficacy of Lactobacillus para- casei-enriched artichokes in the treatment of patients with functional constipation - a double-blind, controlled, crossover study. Aliment Pharmacol Ther 2012 Feb; 35(4):441-50.

40. Favretto D.C., Pontin B., Moreira T.R. Effect of the consumption of a cheese enriched with probiotic organisms (Bifidobacterium lactis bi-07) in improving symptoms of constipation. Arq Gastroenterol 2013 Jul-Sep; 50(3):196- 201.

41. Ojetti V., Ianiro G., Tortora A., D’Angelo G., Di Rienzo T.A., Bibbò S., Migneco A., Gasbarrini A. The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, dou- ble-blind, placebo-controlled trial. J Gastrointest Liver Dis 2014 Dec; 23(4):387-91.

42. Pinn D.M., Aroniadis O.C., Brandt L.J. Is fecal micro- biota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil 2015 Jan; 27(1):19-29.


Рецензия

Для цитирования:


Шульпекова Ю.О., Курбатова А.А., Седова А.В. Запор функционального происхождения. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):105-112. https://doi.org/10.22416/1382-4376-2017-27-5-105-112

For citation:


Shulpekova Yu.O., Kurbatova A.A., Sedova A.V. Functional constipation. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):105-112. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-5-105-112

Просмотров: 1243


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.


ISSN 1382-4376 (Print)
ISSN 2658-6673 (Online)